openPR Logo
Press release

Fact.MR Presents Key Insights on Global Ovarian Cancer Diagnostics Market Based On Product Type, End-use and Regional Demand Till 2022 || Top Market Competitors- Quest Diagnostics Incorporated, Myriad Genetics, AstraZeneca, Epigenomics AG, Illumina, Inc.,

11-16-2018 08:19 AM CET | Health & Medicine

Press release from: Fact.MR

Fact.MR

Fact.MR

As scientists in cancer research organizations continue to develop more advanced diagnosis tests for ovarian cancer, medical device manufacturers are expected to face challenges in adapting to such changes. In the long run, the demand for ovarian cancer diagnostics is expected to gain traction, on the account of rising awareness of ovarian cancer symptoms and higher adoption of screening tests as a preventive measure.

Request For Free Sample Report @ https://www.factmr.com/connectus/sample?flag=S&rep_id=51

The Fact.MR report on global ovarian cancer diagnostics market projects that by the end of 2017, around US$ 638 Mn worth of revenues will be procured globally through diagnosis of ovarian cancer. Emergence of multi-purpose diagnosis tests on ovarian cancer is expected to boost the market’s expansion in the future. Towards the end of 2022, the global market for ovarian cancer diagnostics is anticipated to expand at 8.7% CAGR, bringing in revenues worth a little over US$ 966 Mn.

Epithelial Tumours Segment larger than the other two combined

The Epithelial Tumours Segment is anticipated to grow to almost US $ 880 million by the end of the forecast period and it already accounts for an 11% revenue share in 2017 itself.  North America alone represents almost 2/5th of the market and it should touch US$ 330 million by the end of 2022. The germ cell carcinoma tumours segment is much smaller by comparison and is only poised to be a US$ 50 million market by the end of the five year study. Even the stromal carcinoma tumours segment is marginal at best when contrasted with epithelial tumours in the ovarian cancer diagnostics market. The stromal carcinoma tumours segment is likely to be valued at only US$ 28 million in 2017.

Hospital associated and independent diagnostic labs most vital

The hospital associated lab segment is expected to record a CAGR of 7.8% from 2017-2022 and rise from just under $300 million in 2017 to roughly US$ 440 million in 2022. Independent diagnostic labs are the second most important segment in the ovarian cancer diagnostics market and are estimated to be worth US$ 161 million in 2017. While North America might account for the largest contribution, Europe should record a higher CAGR of 9.5% making it more attractive to target in the long term.

Focus on CA 125 test segment in the ovarian cancer diagnostics market

The CA 125 test segment could be worth roughly US$ 440 million in 2022 and some key stakeholders may decide to focus on this lucrative test over all other available alternatives in the ovarian cancer diagnostics market. However, the HER 2 segment also accounts for a 3.1% revenue share in 2017 and it would be unwise to do so. On the other hand, the BRCA segment in North America alone could grow with a CAGR of 8.3% for the period 2017-2022, making it imperative for companies to hedge their bets in the ovarian cancer diagnostics market.

View Full Report with Table of Content @ https://www.factmr.com/report/51/ovarian-cancer-diagnostics-market

Competition Tracking

The report has also profiled leading players in the global market for ovarian cancer diagnostics, which include Quest Diagnostics Incorporated, Myriad Genetics Inc., AstraZeneca plc., Epigenomics AG, Illumina, Inc., Bio-Rad Laboratories, Inc., Siemens AG, Thermo Fisher Scientific Inc., Roche Holding AG., and Abbott Laboratories.

Key Insights on Global Ovarian Cancer Diagnostics Market:

According to the report, diagnosis of epithelial tumors will procure largest share in the global ovarian cancer diagnostics market. With more than 90% share, over US$ 875 Mn revenues are anticipated to be procured by diagnosis of epithelial tumors in the global market.
Presence of prominent cancer research societies in the US and Canada is anticipated to boost the contribution of North America towards growth of the global ovarian cancer diagnostics market. In 2017, North America will remain dominant region, procuring nearly US$ 240 Mn in revenues. The ovarian cancer diagnostics market in North America is also pegged to exhibit rapid growth by reflecting an estimated CAGR of 8.7%.
Europe’s ovarian cancer diagnostics market is expected to showcase a relatively faster growth in terms of revenues. Robust healthcare infrastructure in a majority of European countries is observed to boost the adoption of ovarian cancer diagnostics in this region. Towards the end of 2022, Europe will record revenues worth a little over US$ 315 Mn in its ovarian cancer diagnostics market.
The report anticipates fastest growth in the Asia-Pacific excluding Japan (APEJ) region. Expanding at an estimated 9.5% CAGR, the ovarian cancer diagnostics market in APEJ region will have procured close to US$ 127 Mn by the end of the forecast period.
On the basis of test-types, CA 125, HER2 and BRCA are anticipated to be prominent diagnostic tests in the global market. Diagnosis of ovarian cancer through CA125 is expected to account for more than 40% of revenues procured throughout the forecast period. Demand for HER2 testing is also expected to gain traction, reflecting an estimated revenue growth at 9.5% CAGR.
The report also observes hospital associated labs as the largest end-users of ovarian cancer diagnostics. In 2017, close to US$ 300 Mn worth of revenues will be procured from hospitals associated labs on ovarian cancer diagnostics.
Grow Your Business From Expert Advice @ https://www.factmr.com/connectus/sample?flag=AE&rep_id=51

Table of Content:

Chapter 1. Global Ovarian Cancer Diagnostics Market - Executive Summary. 26

Chapter 2. Global Ovarian Cancer Diagnostics Market Overview. 28
2.1. Introduction. 28
       2.1.1. Global Ovarian Cancer Diagnostics Market Taxonomy. 28
       2.1.2. Global Ovarian Cancer Diagnostics Market Definition. 28
2.2. Global Ovarian Cancer Diagnostics Market Size (US$ Mn) and Forecast, 2012-2022. 28
       2.2.1. Global Ovarian Cancer Diagnostics Market Y-o-Y Growth. 28
2.3. Global Ovarian Cancer Diagnostics Market Dynamics. 29
       2.3.1. Drivers. 29
       2.3.2. Restraints. 29
       2.3.3. Trends. 29
2.4. Supply Chain. 30
2.5. Epidemiology. 30
2.6. List of Distributors. 30
2.7. Average Pricing Analysis. 30
2.8. Regulations. 30
2.9. Key Participants Market Presence (Intensity Map) By Region. 31

Chapter 3. Global Ovarian Cancer Diagnostics Market Analysis and Forecast By Cancer Type. 32
3.1. Global Ovarian Cancer Diagnostics Market Size and Forecast By Cancer Type, 2012-2022. 32
       3.1.1. Epithelial Tumors Ovarian Cancer Diagnostics Market Size and Forecast, 2012-2022. 32
                3.1.1.1. Revenue (US$ Mn) Comparison, By Region. 32
                3.1.1.2. Market Share Comparison, By Region. 34
                3.1.1.3. Y-o-Y growth Comparison, By Region. 34
       3.1.2. Germ cell carcinoma tumors Ovarian Cancer Diagnostics Market Size and Forecast, 2012-2022. 35
                3.1.2.1. Revenue (US$ Mn) Comparison, By Region. 35
                3.1.2.2. Market Share Comparison, By Region. 37
                3.1.2.3. Y-o-Y growth Comparison, By Region. 37
       3.1.3. Stromal carcinoma tumors Ovarian Cancer Diagnostics Market Size and Forecast, 2012-2022. 38
                3.1.3.1. Revenue (US$ Mn) Comparison, By Region. 38
                3.1.3.2. Market Share Comparison, By Region. 40
                3.1.3.3. Y-o-Y growth Comparison, By Region. 40

Chapter 4. Global Ovarian Cancer Diagnostics Market Analysis and Forecast By End User. 42

Continued……………..

About FactMR
FactMR is a fast-growing market research firm that offers the most comprehensive suite of syndicated and customized market Insights reports. We believe transformative intelligence can educate and inspire businesses to make smarter decisions. We know the limitations of the one-size-fits-all approach; that's why we publish multi-industry global, regional, and country-specific research reports.

Contact Us
FactMR
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Email: sales@factmr.com
Web: https://www.factmr.com/
Follow Us on Linkedin: https://www.linkedin.com/company/factmr/

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Fact.MR Presents Key Insights on Global Ovarian Cancer Diagnostics Market Based On Product Type, End-use and Regional Demand Till 2022 || Top Market Competitors- Quest Diagnostics Incorporated, Myriad Genetics, AstraZeneca, Epigenomics AG, Illumina, Inc., here

News-ID: 1375807 • Views: 647

More Releases from Fact.MR

07-02-2020 | Health & Medicine
Fact.MR
Medical Device Contract Manufacturing Market Set for Strong Growth, Production F …
The medical device contract manufacturing market is poised to expand at a CAGR of 11.3% during the forecast period (2020-2026). This is attributed to rapidly evolving healthcare industry and increasing adoption of technologically advanced surgical procedures. A number of original equipment manufacturers (OEMs) and contract manufacturers have been focusing on advanced technologies such as robotics, 3D-printing, and minimally invasive surgeries. Mergers & acquisition activities among leading players have greatly accelerated
06-02-2020 | Health & Medicine
Fact.MR
Fluid Management Market Expected to Grow Amid Covid-19, Finds Fact.MR
Growing prevalence of chronic disease and an expansion in numbers of geriatric population is leading to an upward facing growth curve for global fluid management market over the period of 2020 to 2025, states Fact.MR. It projects a compound annual growth rate or CAGR of about 5.3% for the market over this period, helping the market push its worth up significantly. It is significant to note here that while number of
Hand Sanitizer Market to Surpass US$ 2.8 Bn, Instant Hand Sanitizer Poised to Ho …
The global hand sanitizer market is set to surpass a value of ~US$ 1.4 Bn in 2020 and is anticipated to cross US$ ~2.8 Bn during the forecast period 2020-2030. The demand for gel-based sanitizer is on the rise as compared to foaming or spray sanitizer. Thus, manufacturers are focusing on developing gel-based sanitizers as they are widely used in multiple end-use industries. With the increased penetration of the online
03-20-2020 | Health & Medicine
Fact.MR
Medical Marker Bands Market Grows on the back of Their Radiopacity and Cost-effe …
Radiopacity of medical marker bands is giving significant impetus to their demand in the medical marker bands market. The properties of medical marker bands that increases their visibility under fluoroscopes or x-ray during critical procedures is giving an uptick to their sales worldwide. Manufacturers of medical marker bands are also showing a marked preference for cost-effective materials such as polymer and tantalum instead of traditional gold, platinum and palladium. On

All 5 Releases


More Releases for Cancer

Cancer Vaccines Market
Manufacturers in the cancer vaccines market are focusing on developing new vaccines in order to treat various cancers. Through this, they are expected to gain a competitive edge in the market and increase their market share. For instance, Gilead Science Inc., in 2017, acquired Kite Pharma Inc., which is involved in development of different type of immunotherapy and vaccines. Also, Treos Bio, in 2017, collaborated with Pharmaceutical Product Development, LLC
Oncology Nutrition Market by Cancer Type Breast Cancer, Liver Cancer, Lung Cance …
Lunch of new products for nutrition of oncology patients is expected to drive the oncology nutrition market growth. For instance, in 2016, Hormel Food Corporation, a U.S-based meat food products company, launched a line of packaged ready-to-eat meals for cancer patients, which are called as Hormel Vital Cuisine. These meals consist of carbohydrates, proteins, and fats to help patients fight loss of muscle mass and energy during cancer treatment. Thus launch
Cancer Molecular Biomarkers Market
Cancer molecular biomarkers refer to naturally-occurring molecules or genes in living organisms, which is an indicator for the presence of cancer in the body. A biomarker is a measurable indicator of biological process, condition, or disease and can be found in the blood, tissues, or other body fluids. Cancer molecular biomarkers help to diagnose cancer and monitor patients’ responses to treatments. On the basis of diagnostics, the cancer molecular
Cancer Diagnostics Global Market: By Application - Breast Cancer, Lung Cancer, C …
Researchmoz added Most up-to-date research on "Cancer Diagnostics Global Market: By Application - Breast Cancer, Lung Cancer, Colorectal Cancer, Melanoma & Other Cancers" to its huge collection of research reports. This report studies Cancer Diagnostics in Global market, especially in North America, China, Europe, Southeast Asia, Japan and India, with production, revenue, consumption, import and export in these regions, from 2012 to 2016, and forecast to 2022. This report focuses on top
Global Cancer Vaccines Market 2016: Liver cancer, Cervical cancer, Stomach cance …
Latest industry research report on Cancer vaccines are the type of immunotherapy (also named as biologic therapy), designed to boost body's natural defense against cancer. The body's natural immune system recognizes vaccine proteins as the foreign particles and sets up an immunity against them. According to World Health Organization (WHO), cancer is a leading cause of worldwide mortality registering ~14 million new cases and ~8.2 million cancer-related diseases in 2012. Personalized
Taking thyroid cancer seriously
With the increasing incidence rate of thyroid cancer in Metro Cebu, the Eduardo J. Aboitiz Cancer Center (EJACC) of the Ramon Aboitiz Foundation Inc. (RAFI) urged the public to undergo early screening and prevention measures to fight the disease. “Thyroid cancer is high on prognosis. It is preventable through various screening methods, such as physical examination and ultrasound of the neck, as well as some prevention measures, including regular exercise and